

Research

Prevalence of hepatitis B virus in patients with diabetes mellitus: a comparative cross sectional study at Woldiya General Hospital, Ethiopia

Daniel Mekonnen^{1,2}, Solomon Gebre-Selassie², Surafel Fantaw³, Andualem Hunegnaw⁴, Adane Mihret^{2,5,&}

¹Bahir Dar Regional Health Research Laboratory Center, Bahir Dar, Ethiopia, ² Department of Medical Microbiology, Immunology and Parasitology College of Health Science, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia, ³ Ethiopian Health and Nutrition Research Institute Bacteriology and Mycology Laboratory, Addis Ababa, Ethiopia, ⁴Amhara National Regional State Health Bureau, Woldiya General Hospital, Woldiya, Ethiopia, ⁵Armauer Hansen Research Institute, Addis Ababa, Ethiopia

[&]Corresponding author: Adane Mihret, Department of Medical Microbiology, Immunology and Parasitology College of Health Science, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia / Armauer Hansen Research Institute, Addis Ababa, Ethiopia

Key words: Prevalence, HBV, diabetes, non diabetes, association

Received: 17/02/2013 - Accepted: 12/12/2013 - Published: 21/01/2014

Abstract

Introduction: The overall prevalence of HBV in Ethiopia varies from 4.7-16.8% for Hepatitis B surface antigen (HBsAg) and 70-76.38% for at least one marker positive. Patients suffering from type I Diabetes Mellitus (DM) incur high risk of infection with hepatotropic viruses because of frequent hospitalization and blood tests. **Methods:** A comparative cross sectional study was conducted at Woldiya General Hospital using 108 consented study populations from Diabetes and 108 non diabetes control groups during the period November 2010 - January 2011. VISITECT HBsAg rapid test kit and Humastat 80 chemistry analyzer were used. Multivariate logistic regression was used to see the association of HBV with clinical history of participants and Sociodemographic variables. All tests were two-sided with α -level of 0.05 and 80% power. **Results:** Prevalence of HBsAg was equal between diabetic and non diabetic individuals, 3.7% indicating that there was no difference between the two groups. Only history of invasive procedures and chronic liver disease showed association with HBsAg seropositivity. **Conclusion:** In this study a positive relation was not indicated between HBV and Diabetes and the prevalence of HBsAg was equal between diabetic and non diabetic individuals.

Pan African Medical Journal. 2014; 17:40 doi:10.11604/pamj.2014.17.40.2465

This article is available online at: <http://www.panafrican-med-journal.com/content/article/17/40/full>

© Daniel Mekonnen et al. The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Hepatitis B Virus (HBV) infection and its sequelae (cirrhosis and liver cancer) are major global health problems. It has been estimated that up to 2 billion individuals have evidence of exposure to HBV and an estimated 350 million persons worldwide are chronically infected with HBV [1, 2]. Most of these came from East Asia and sub-Saharan Africa [3, 4]. Approximately 470 million inhabitants of Africa are infected with this virus at some time during their lives and about 10% remain infected. Overall prevalence in Ethiopia varies from 4.7-16.8% for Hepatitis B surface antigen (HBsAg) and 70-76.38% for at least one marker positive [5-10].

Viruses are involved in the pathogenesis of type I Diabetes Mellitus (DM) in at least two distinct ways: (a) by directly destroying insulin-producing pancreatic β -cells by cytolytic infection, and (b) by triggering or somehow contributing to β -cell-specific autoimmunity, leading to the development of type I DM [11].

Patients suffering from type I DM incur high risk of infection with hepatotropic viruses because of frequent hospitalization and blood tests [12]. A well-documented, yet under-acknowledged risk associated with blood glucose monitoring is the transmission of blood borne viral pathogens such as HBV [13].

Many chronically infected persons show no outward signs of HBV infection, therefore screening for hepatitis B is necessary to: Identify individuals who have chronic HBV infection so they can receive appropriate medical management; Identify those who are unprotected so they can be vaccinated [14]. Individuals born in areas of high or intermediate prevalence rates for HBV (like Africa and Asia) including immigrants and adopted children should be screened [2, 4].

Methods

A cross sectional comparative study was conducted at Woldiya Zonal Hospital which is found in north Wollo zone in Amhara region, Ethiopia from November, 2010 to January, 2011. One hundred and eight Diabetic patients with age between 18 and 60 years, who came to the Hospital during the study period, were included in the study. One hundred and eight healthy individuals were included as controls.

Information for socio demographic data, history of exposure for the possible associated factors, type of diabetic and years of follow up (only for diabetic patients) was collected using structured questionnaire. The participant serologic status for HBsAg, SGOT and SGPT levels was done using **VISITECT HBsAg** (UK, Omega) rapid test kit and humastar 80 chemistry analyzer respectively.

Data entered and analyzed using SPSS version 16. Variables descriptively expressed as mean \pm SD or number and percent. Comparisons between groups made using Student's t test for continuous variables and Chi-square or Fisher's exact test for categorical data. A multivariate logistic regression model used to determine the independent effect of various factors that were potentially associated with the risk of hepatitis in both groups. All tests were two-sided with α -level of 0.05 and 80% power.

Ethical clearance was obtained from the Institutional Research and Ethics Committee of College of Health science, Addis Ababa University.

Results

A total of 216 participants were included in this study, of whom 108(50%) participants were diabetes patients and the rest 108(50%) were non diabetes healthy controls. Sex, weight, level of

education, smoking, alcohol consumption and most of clinical characteristics were comparable between diabetes and non diabetes control (Table 1). In the study, 96 (44.4%) were female and 120 (55.6%) were male. Mean age and weight of participants were 33.4 years and 54.3 kg respectively. Of the total 216 study participants, 90(41.7%) were married, 80(37%) were single, 36(16.7%) were divorced and 10(4.6%) were widowed. Majority of participants 80(37%) were illiterate and 91(42.1%) were farmers. With regard to diabetes participants, most of them, 75 (69.4%) were type I diabetes and 33 (30.6%) were type II diabetes. Among the 216 participants, 21(9.7%) had abnormal alanine aminotransferase (ALT) (>40 IU/l) and 43(19.9%) had abnormal aspartate aminotransferase (AST) (>40 IU/l) (table 1). Of the total 216 study participants, 8 (3.7%) subjects were positive for HBsAg, four from each of diabetes (3.7%) and non diabetes (3.7%) indicating that there was no significant difference between the prevalence of HBsAg in diabetes patients and in non diabetes controls (Odds Ratio (OR)=1.00; 95% CI: 0.244-4.1; $p=1.00$). Among positive participants, four were females and the rest four were males showing no difference between female and male participants.

In this study we tried to observe the association of the presence of HBsAg with sociodemographic variables; and clinical characteristics of the study participant using multivariate logistics regression method. Except history of liver disease and invasive procedures, no clinical and sociodemographic characteristics were associated with HBV infection in our study (table 2 and 3).

Discussion

In this study, the prevalence of HBsAg in diabetic patients and non diabetes controls was the same and estimated to be (3.7% versus 3.7%; Odds Ratio (OR) =1.00; 95% CI: 0.244-4.1; $p=1.00$) indicating that there was no significant difference in the prevalence rate of HBsAg seropositivity between diabetic patients and the control population. These findings showed that the vast majority of patients with diabetes have no increased susceptibility to infection by HBV than the general population. This study also showed that the study area to be of intermediate endemicity (2-8%) with HBV and consistent with previous serologic data from most region of Ethiopia [5,8-10].

We compared diabetes and non diabetes with some sociodemographic variables and LFT values, except age, all the sociodemographic variables (weight, sex, smoking and alcohol consumption) did not show any difference indicating that the two groups are comparable. The difference age was due to the fact that that controls were VCT clients who came to VCT for marital purpose. The LFT result showed difference between diabetes and non diabetes in this study. The prevalence of high ALT levels may reach 20% in diabetes. Elevation of these enzymes is strongly related to obesity, diabetes and dyslipidemia, and their measurement may act as a surrogate marker of non alcoholic fatty liver disease (NAFLD) presence [15, 16].

Association was obtained between HBsAg positivity and history of invasive procedures like tooth extraction, abortion and body piercing. This association is reasonably accepted. In the study area practice of unsafe tooth extraction, abortion and tattooing is widely common and it agrees with Negero *et al* (2011) study [10].

History of liver disease was significantly associated with HBsAg. The main cellular target of HBV is the hepatocyte, and in humans, these are the only cells convincingly shown to replicate the virus. HBV is responsible for a chronic hepatitis, leading to cirrhosis and liver cancer in many parts of the world [17]. HBV is causally associated with primary hepatocellular carcinoma (PHC) [18].

The serum alanine aminotransferase was normal in both groups. Normal serum alanine aminotransferase (ALT=34.8 IU/l \pm 13.8 SD)

levels in patients with HBsAg in our result may indicate the inactive HBsAg carrier state (After spontaneous HBeAg seroconversion, 67% to 80% of carriers have low or undetectable HBV DNA and normal ALT levels with minimal or no necroinflammation on liver biopsy) [2, 19] or may reflect mild chronic hepatitis B or hepatitis B with fluctuating disease activity [20].

Aspartate aminotransferase was higher than the normal value (AST=49.8 IU/l \pm 25.2 SD) but statistically not different from the sero negative group (AOR=9.6; 95% CI: 0.18-502; P=0.26), one of the reasons for this situation might be the effect of diabetes. The presence of diabetes remained an independent risk factor for chronic liver diseases and HCC after adjustment for alcohol use or viral hepatitis in the studies that evaluated these factors [21].

History of transfusion and history of alcohol consumption were not associated with HBsAg in our study. All this results were consistent with Shimelis *et al*, 2007 study. Transfusion with blood or blood products is no longer an important risk factor for acute viral hepatitis [2, 20].

History of multiple sexual partners did not associate with HBsAg positivity in our study. hemodialysis also did not associate with hepatitis seropositivity in contrast to [22] study. As we can see from table 2 and 3; the confidence interval is so wide indicating that the sample size is small and the point estimate is imprecise. Because of these reason, we could not strongly conclude that the aforementioned clinical characteristics, laboratory and sociodemographic variables did not associated with HBV infection.

Many previous studies, conducted in various nations, including Taiwan (13.5%Vs12.4%) [23], South Africa (4.6%Vs 4.3%) [24], Turkey (3.4%Vs 2.2%) [25], Nigeria (20% Vs17.3%) [26] and Turkey (5.1%Vs 3.8%) [27] reported a higher prevalence rate of hepatitis B in diabetic patients than non diabetic, but no significant difference was found. Our finding which (3.7% Vs 3.7%) was apparently consistent with the above mentioned studies as there was no statistical difference between diabetes and non diabetes. Unlike other studies our result showed equal prevalence between diabetes and non diabetes. This might be due to small sample size that we used as indicated by wide range of confidence interval; (AOR=1.00; 95% CI: 0.244-4.1) and chance as indicated by p-value (p=1.00).

Studies done in Ethiopian on different target population, for example a study done by Abebe *et al* (2003) [5] in Addis Ababa residents, Shimelis *et al* (2007) [8] at Saint Paul's General Specialized Hospital on VCT clients, by Tessema *et al* (2010) [9] at University of Gondar on blood bank and by Negero *et al* (2011) [10] among VCT clients at Shashemene Hospital showed 7%, 5.7%, 4.7% and 5.7% HBsAg prevalence, respectively. When we compared these finding with ours, they showed intermediate endemicity prevalence like the current study but slightly higher. The possible reason for these differences might be due to differences in method, type of lab test kit used; sample size, geographic distribution and socio demographic variables.

Our low prevalence might also be attributed to the failure to identify infected patients because of the serologic window during the incubation period following infection, the presence of some rare variants escaping the serologic assay for HBsAg, particularly when concurrent testing for anti-HBc is not performed [17] and the problem of occult HBV infections [2, 17] in which neither HBsAg or anti-HBc are detected [17]. Since the assay is serologic, there might be false negative, especially for HBV, patient antibody may be bound with viral antigen in immune complexes, thereby preventing antibody detection [18].

Generally this study and other previous studies conducted in Ethiopia showed lower prevalence than WHO report of greater than 8% for HBsAg. This discrepancy might be due to study designs, because in endemic area of Africa and Asia, most infections occurs in infants and children as a result of maternal-neonatal transmission or close childhood contact [2, 4] and these studies done on adults

which have lower prevalence than infants, children and special group of populations who are at special risk making the prevalence of these study lower than WHO report.

Conclusion

Generally our findings suggest that DM has no any association with HBV infection and the prevalence of HBV is similar in both diabetic cases and control groups and therefore diabetic patients would require no special anti HBV prophylaxis than the general population.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

Daniel Mekonnen , Solomon Gebre-Selassie, and Adane Mihret conceived, initiated and designed the study. Daniel Mekonnen ,Surafel Fantaw and Andualem Hunegnaw , conducted the laboratory work, undertook statistical analysis and drafted the manuscript. Andualem Hunegnaw recruited study participants. Adane Mihret and Solomon Gebre-Selassie corrected the manuscript. All authors contributed to the writing of the manuscript and approved the submitted version of the manuscript.

Acknowledgments

The authors thank Addis Ababa University School of graduate studies, Department of Medical Microbiology ,Immunology and Parasitology for funding this study. We are also thankful to Amhara National Regional State Health Bureau, Woldiya general Hospital, Tefera Hailu Memorial Hospital and laboratory staffs of Woldiya general Hospital for their help in one or the other way. The manuscript is based on an MSc thesis of the first author, which was published in the Addis Ababa University, Ethiopia.

Tables

Table 1: Comparison of Sociodemographic, rate of HBsAg positivity and LFT values between DM patients and control subjects, Woldiya, 2011

Table 2: Sociodemographic variables and status of diabetes types related to the risk of HBV, Woldiya, 2011

Table 3: Clinical characteristics and LFT value related to the risk of HBV between HBsAg positive and negative subjects, Woldiya, 2011

References

1. A professional's guide to hepatitis B. British Liver Trust 2009. Southampton Road and Ringwood, BH24 1HY. **Google Scholar**
2. Lok ASF and McMahon BJ. Chronic Hepatitis B: Update. American Association for the Study of Liver Diseases (AASLD) Practice Guidelines Hepatology. 2009; 50 (3): 1-36. **PubMed | Google Scholar**

3. Edmunds WJ, Medley GF, Nokes DJ, O'callaghan C J, Whittle HC, Hall AJ. Epidemiological Patterns of Hepatitis B Virus in Highly Endemic Areas. *Epidemiol Infect.*1996; 117(2):313-325. **PubMed | Google Scholar**
4. WHO. Department of communicable diseases surveillance and response. 2002. Hepatitis B. Online available from <http://WWW.who.int/emt>. Accessed on June 23, 2012. **PubMed | Google Scholar**
5. Abebe A, Nokes J, Dejene A, Enquesselassie F, Messele T, Cutts T. Seroepidemiology of hepatitis B virus in Addis Ababa Ethiopia: transmission patterns and vaccine control. *Epidemiol Infect.* 2003; 131(1): 756-770. **PubMed | Google Scholar**
6. Kefenig H, Rapicetta M, Rossi G B, Bisanti L, Bekura D, Morace G, Palladino P, Rienzo A D, Conti S, Bassani F, Bertolaso G, Pasquini P. A nationwide seroepidemiological study of hepatitis B markers prevalence was conducted in Ethiopia on 5,270 young males from all regions of the country. *Journal of Medical Virology.* 2005; 24(1): 75-84. **PubMed | Google Scholar**
7. Pasquini P, Bisanti L, Soldo L, Palladino P, Rozera C, Frontini E, Miozzo A, Di Gennaro TM, Indi A, Conti S, et al. Hepatitis B infections in the Arsi region of Ethiopia. *Eur J Epidemiol.*1988; 4(3):310-313. **PubMed | Google Scholar**
8. Shimelis T, Torben W, Medhin G, Tebeje M, Andualm A, Demessie F, Mulu A, Tegbaru B and Gebre-Selassie S. Hepatitis B virus infection among attendants of VCT and ART clinic of Saint Paul's General Specialized Hospital, Addis Ababa, Ethiopia. *Sex Transm Infect.* 2007; 84(1):37-41. **PubMed | Google Scholar**
9. Tessema B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F, Sack U. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. *BMC Infectious Diseases.* 2010; 10(111):1-7. **PubMed | Google Scholar**
10. Negero A, Sisay Z, Medhin G. Prevalence of Hepatitis B surface antigen (HBsAg) among visitors of Shashemene General Hospital voluntary counseling and testing center. *BMC Research Notes.* 2011; 4 (35):1-5. **PubMed | Google Scholar**
11. Won Yoon J and Sook Jun H. *Diabetes Mellitus: A Fundamental and Clinical Text.*3rd Edition. 2004. Lippincott Williams & Wilkins. **PubMed | Google Scholar**
12. Halota W, Muszynska M, Pawlowska M. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. *Med Sci Monit.* 2002; 8(7):516-519. **PubMed | Google Scholar**
13. Thompson Nicola D. and Perz Joseph F. Eliminating the Blood: Ongoing Outbreaks of Hepatitis B Virus Infection and the Need for Innovative Glucose Monitoring Technologies. *Journal of Diabetes Science and Technology.* 2009; 3(2):283-288. **PubMed | Google Scholar**
14. Physician's guide to Hepatitis B a silent killer. 2007. Asian Liver Center at Stanford University. **Google Scholar**
15. Judi L, Toukan A, Khader Y, Ajlouni K, and Khatib M. Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus. *Ann Saudi Med.* 2010; 30 (1): 25-32. **PubMed | Google Scholar**
16. Sheth S, G and Chopra S. Pathogenesis, clinical features, and diagnosis of nonalcoholic steatohepatitis. *Uptodate.* 2010;18(2):1-8. **PubMed | Google Scholar**
17. David M, Peter M. *Fields Virology.* 5th Edition. 2007. Lippincott Williams & Wilkins. 2978-3014. **PubMed | Google Scholar**
18. Murray P R, Rosenthal K S, P faller M A. *Medical Microbiology.*5th ed. 2005. Elsevier Mosby. **PubMed | Google Scholar**
19. Sharma S.K, Saini N, Chwla Y. Hepatitis B Virus: Inactive carriers. *Virology Journal.* 2005; 2 (82):1-5. **PubMed | Google Scholar**
20. Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscazo. *Harrison's Principles of Internal Medicine .Seventeenth Edition.* 2008. The McGraw-Hill Companies, Inc. **PubMed | Google Scholar**
21. Blonski W, Kotlyar D S, Forde K A. Non-viral causes of hepatocellular carcinoma. *World J Gastroenterol.* 2010; 16(29): 3603-3615. **PubMed | Google Scholar**
22. El-Ottol A, Elmanama A, Ayesh B. Prevalence and risk factors of hepatitis B and C viruses among haemodialysis patients in Gaza strip, Palestine. *Virology Journal.* 2010; 7: 210. **PubMed | Google Scholar**
23. Chen H-F, Yi Li Ch, Chen P, Ting T, Yu Lee H. Seroprevalence of Hepatitis B and C in Type 2 Diabetic Patients. *J Chin Med Assoc.* 2006; 69(4):146-152. **PubMed | Google Scholar**
24. Kew MC, Mackay M E, Mindel A, Joffe B, Kusman B, Macnab G M, Seftel H C. Prevalence of Hepatitis B Surface Antigen and Antibody in White and Black Patients with Diabetes Mellitus. *Journal of Clinical Microbiology.* 2001; 4(6): 467-469. **PubMed | Google Scholar**
25. Kilic D, Kaygusuz S, Agalar C , Guliter S , Cakmak A and Sezikli M. HGV prevalence in patients with Type II diabetes mellitus and HGV infection. *J Infect Developing Countries.* 2007; 1(2):189-194. **PubMed | Google Scholar**
26. Onyekwere CA, Anomneze EE, Wali S. Prevalence of serological markers of chronic hepatitis B virus infection in diabetics in the Lagos University Teaching Hospital, Lagos. *Niger Postgrad Med J.* 2002; 9(3): 129-133. **PubMed | Google Scholar**
27. Gulcan A, Gulcan E, Toker A, Bulut I, Akcan Y. Evaluation of risk factors and seroprevalence of hepatitis B and C in diabetic patients in Kutahya, Turkey. *J Investig Med.*2008;56(6):858-863. **PubMed | Google Scholar**

Table 1: Comparison of sociodemographic, rate of HBsAg positivity and LFT values between DM patients and control subjects, Woldiya, 2011

	Diabetic patients	Control subjects	p-value
Age (mean)	37.6±13	29.2±10.4	0.001
Weight (mean)	54.6±4.8	54.1±5	0.824
Sex (n)			
<i>Male</i>	57 (52.8%)	63 (58.3%)	0.494
<i>female</i>	51 (47.2%)	45 (41.7%)	
ALT (Iu/l)	25.2±1	20.5±11.7	0.001
AST (Iu/l)	30.4±13	27.8±15.7	0.001
HBsAg (n)			
<i>Positive</i>	4 (3.7%)	4 (3.7%)	1.000
<i>negative</i>	104 (96.3%)	104 (96.3%)	
Active smoking (n)			
<i>Yes</i>	1 (1%)	3 (2.8%)	0.614
<i>no</i>	107 (99%)	105 (97.2%)	
Alcohol consumption (n)			
<i>Yes</i>	9 (9.3%)	32 (29.6%)	0.00*
<i>no</i>	99 (91.7%)	76 (70.4%)	
Total	108 (100%)	108 (100%)	

Table 2: Sociodemographic variables and status of diabetes types related to the risk of HBV, Woldiya, 2011

Sociodemographic characteristics	HBV positive, N (%)	HBV negative, N (%)	AOR	P-value
Age				
<i>18-45</i>	6 (75)	170 (81.7)	1	0.507
<i>46-60</i>	2 (25)	38 (18.3)	1.95 (0.27-13.9)	
Sex:				
<i>Female</i>	4 (50)	92 (44.3)	1	0.743
<i>Male</i>	4 (50)	116 (55.7)	1.38(0.2-9.63)	
Marital status				
<i>Marriage</i>	4 (50)	86 (43.4)	1	
<i>Single</i>	2 (25)	78 (37.5)	0.49(0.003-3.9)	0.501
<i>Divorced</i>	2 (25)	34 (16.3)	1.64(0.22-12.4)	0.60
<i>widowed</i>	0 (0)	10 (4.8)	NA	0.999
Educational status				
<i>Illiterate</i>	4 (50)	76 (36.5)	1	
<i>Primary school</i>	1 (12.5)	65 (31.2)	0.22(0.02-2.79)	0.245
<i>Secondary school</i>	1 (12.5)	19 (9.1)	0.84(0.05-13.7)	0.903

<i>Diploma and above</i>	2 (25)	48 (23.1)	0.395(0.03-6.2)	0.509
Occupation				
<i>Has no job</i>	1 (12.5)	19 (9.1)	1	
<i>Government employee</i>	2 (25)	18 (8.7)	3.7(0.168-80.5)	0.409
<i>Farmer</i>	3 (37.5)	88 (42.3)	0.34(0.03-4.5)	0.408
<i>Private employee</i>	2 (25)	83 (40)	0.39(0.03-6.2)	0.504

Table 3: Clinical characteristics and LFT value related to the risk of HBV between HBsAg positive and negative subjects, Woldiya, 2011

Clinical Characteristics	HBsAg positive, N (%)	HBsAg negative, N (%)	AOR	P-value
History of jaundice(chronic liver disease)				
<i>no</i>	7 (87.5)	206 (99.04)	1	0.022
<i>Yes</i>	1 (12.5)	2 (.96)	448(2.45-8.22)	
History of hospital admission				
<i>no</i>	6 (75)	137 (65.9)	1	0.069
<i>Yes</i>	2 (25)	71 (34.1)	0.021(0-1.35)	
History of surgical operation				
<i>no</i>	6 (75)	186 (89.4)	1	0.599
<i>Yes</i>	2 (25)	22 (10.6)	0.42(0.02-10.7)	
History of blood transfusion				
<i>no</i>	7 (87.5)	201 (96.6)	1	0.099
<i>Yes</i>	1 (12.5)	7 (3.4)	128(0.4-4.16)	
History of hemodialysis (CKD)				
<i>no</i>	7 (87.5)	190 (91.3)	1	0.583
<i>Yes</i>	1 (12.5)	18 (8.7)	2.8(0.07-113.9)	
Receiving corticosteroids or immunosuppressive drugs				
<i>no</i>	7 (87.5)	194 (93.3)	1	0.478
<i>yes</i>	1 (12.5)	14 (6.7)	0.26(0.006-10.5)	
History of household contacts				
<i>no</i>	8 (100)	205 (98.6)		0.999
<i>Yes</i>	0 (0)	3 (1.4)	NA	
History of multiple sexual partner				
<i>no</i>	6 (75)	141 (67.8)	1	0.799
<i>Yes</i>	2 (25)	67 (32.2)	1.32(0.16-10.9)	
Invasive procedures*				
<i>No</i>	3(37.5)	145(69.7)	1	0.048
<i>Yes</i>	5(62.5)	63(30.3)	9.4(1.02-86.8)	
GPT				
<i><24 Im/l</i>	1 (12.5)	125 (60)	1	
<i>24-40 Im/l</i>	5 (62.5)	64 (30.8)	9.6(0.23-392)	0.233
<i>>40 Im/l</i>	2 (25)	19 (9.2)	2.73(0.04-185)	0.641
GOT				

<24 <i>Im/l</i>	1 (12.5)	87(41.8)	1	
24-40 <i>Im/l</i>	1 (12.5)	84(40.4)	0.402(0.007-23)	0.661
>40 <i>Im/l</i>	6 (75)	37(17.8)	9.6 (0.18-502)	0.263
*=abortion, tooth extraction, ear piercing, and tattooing				